Functional benefits of a chorioretinal anastomosis at 2 years in eyes with a central retinal vein occlusion treated with ranibizumab compared with ranibizumab monotherapy.
Ian L McAllisterLynne A SmithiesFred K ChenDavid A MackeyPaul G SanfilippoPublished in: BMJ open ophthalmology (2021)
For patients with CRVO, adding L-CRA as a causal-based treatment to conventional therapy reduced CVP and injection loads and offered improved BCVA.Trial registration number ACTRN12612000004864.